Julian Harrison, an analyst from BTIG, maintained the Buy rating on Protagonist Therapeutics (PTGX – Research Report). The associated price target is $41.00. Julian Harrison has given his Buy rating
Julian Harrison, an analyst from BTIG, maintained the Buy rating on Protagonist Therapeutics (PTGX – Research Report). The associated price target is $41.00. Julian Harrison has given his Buy rating
Protagonist Therapeutics has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of today and expects to meet the trial’s 250 patient
Protagonist Therapeutics (PTGX) announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda (TAK) disclosed on January 31, 2024. Closing of the transaction was contingent on
העסקה הזו הופץ לראשונה ב-31 בינואר 2024. הם היו צריכים לחכות לאישור תחת חוק אמריקאי בשם חוק שיפורי האנטי-טראסט הארט-סקוט-רודינו של שנת 1976. עכשיו, כשיש להם את האישור הזה, Protagonist
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a price target of $38.00. Douglas Tsao has